News >

Expert Sheds Light on Lesser-Known Mutations in NSCLC

Angelica Welch
Published: Friday, Dec 22, 2017

Raghava R. Induru, MD

Raghava R. Induru, MD
Molecular subtyping through next-generation sequencing has revolutionized the treatment paradigm of lung cancer diagnosis and treatment, according to Raghava R. Induru, MD.


OncLive: Please provide an overview of your presentation.

Induru: The entire paradigm of treatment and testing in lung cancer has completely changed, and will continue to evolve over the next several years. From the common concept of lung cancer to molecular subtyping, the door has opened for newer and better treatments, which improve the quality of life of all patients with lung cancer. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication